Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020413 citationsJournal Articlebronze Open Access

Authors

Cora N. Sternberg · Weill Cornell Medicine

Karim Fizazi · Université Paris-Saclay

Fred Saad · Université de Montréal

Neal D. Shore · Carolina Urologic Research Center

Ugo De Giorgi

David F. Penson · Vanderbilt University

Ubirajara Ferreira · Pontifícia Universidade Católica de Campinas

Abstract

Enzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. The risk of death associated with enzalutamide was 27% lower than with placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924.).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Hormonal and reproductive studies

UN Sustainable Development Goals

No poverty

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 23, pp. 2197-2206

DOI: 10.1056/nejmoa2003892

Field-Weighted Citation Impact: 34.56